1. Home
  2. MED vs MDWD Comparison

MED vs MDWD Comparison

Compare MED & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MEDIFAST INC

MED

MEDIFAST INC

HOLD

Current Price

$12.33

Market Cap

120.6M

ML Signal

HOLD

Logo MediWound Ltd.

MDWD

MediWound Ltd.

HOLD

Current Price

$19.10

Market Cap

230.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MED
MDWD
Founded
1980
2000
Country
United States
Israel
Employees
N/A
N/A
Industry
Packaged Foods
Medicinal Chemicals and Botanical Products
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
120.6M
230.7M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
MED
MDWD
Price
$12.33
$19.10
Analyst Decision
Hold
Strong Buy
Analyst Count
1
2
Target Price
$16.50
$37.50
AVG Volume (30 Days)
205.6K
92.0K
Earning Date
11-03-2025
11-20-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.02
N/A
Revenue
$429,695,000.00
$20,932,000.00
Revenue This Year
N/A
$15.89
Revenue Next Year
N/A
$25.33
P/E Ratio
$592.83
N/A
Revenue Growth
N/A
6.15
52 Week Low
$10.36
$14.14
52 Week High
$21.98
$22.51

Technical Indicators

Market Signals
Indicator
MED
MDWD
Relative Strength Index (RSI) 66.00 59.17
Support Level $10.72 $18.71
Resistance Level $11.12 $19.63
Average True Range (ATR) 0.34 0.71
MACD 0.22 0.18
Stochastic Oscillator 98.20 76.67

Price Performance

Historical Comparison
MED
MDWD

About MED MEDIFAST INC

Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. OPTAVIA provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. Medifast remains committed to its mission of offering Lifelong Transformation, Making a Healthy Lifestyle Second Nature.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: